CN116744958A - 骨关节炎疼痛的治疗 - Google Patents

骨关节炎疼痛的治疗 Download PDF

Info

Publication number
CN116744958A
CN116744958A CN202280011039.6A CN202280011039A CN116744958A CN 116744958 A CN116744958 A CN 116744958A CN 202280011039 A CN202280011039 A CN 202280011039A CN 116744958 A CN116744958 A CN 116744958A
Authority
CN
China
Prior art keywords
pain
link
tsg6
gly
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280011039.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·戴
C·米尔纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Publication of CN116744958A publication Critical patent/CN116744958A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202280011039.6A 2021-01-20 2022-01-19 骨关节炎疼痛的治疗 Pending CN116744958A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2100761.2A GB202100761D0 (en) 2021-01-20 2021-01-20 Treatment of osteoarthritic pain
GB2100761.2 2021-01-20
PCT/EP2022/051101 WO2022157181A1 (en) 2021-01-20 2022-01-19 Use of link-tsg6 for the treatment of osteoarthritic pain

Publications (1)

Publication Number Publication Date
CN116744958A true CN116744958A (zh) 2023-09-12

Family

ID=74679050

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280011039.6A Pending CN116744958A (zh) 2021-01-20 2022-01-19 骨关节炎疼痛的治疗

Country Status (8)

Country Link
US (1) US20250121028A1 (enExample)
EP (1) EP4281098A1 (enExample)
JP (1) JP7896251B2 (enExample)
KR (1) KR20230142502A (enExample)
CN (1) CN116744958A (enExample)
CA (1) CA3204755A1 (enExample)
GB (1) GB202100761D0 (enExample)
WO (1) WO2022157181A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910645D0 (en) 2019-07-25 2019-09-11 Univ Manchester Treatment for dry eye disease
GB202416087D0 (en) 2024-10-31 2024-12-18 Link Biologics Treatment of ocular disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9878003B2 (en) * 2006-03-06 2018-01-30 The University Of Manchester Method of treating bone disorders using TSG-6
CN104703146B (zh) 2013-12-09 2019-03-08 腾讯科技（深圳）有限公司 信息推送方法、客户端及系统

Also Published As

Publication number Publication date
EP4281098A1 (en) 2023-11-29
KR20230142502A (ko) 2023-10-11
GB202100761D0 (en) 2021-03-03
CA3204755A1 (en) 2022-07-28
US20250121028A1 (en) 2025-04-17
JP7896251B2 (ja) 2026-07-29
JP2024504683A (ja) 2024-02-01
WO2022157181A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
Tobinick et al. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept
Soueidan et al. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin
US8389479B2 (en) Compositions and methods for treatment of multiple sclerosis
CN104955843B (zh) 治疗杜兴氏肌营养不良的抗flt-1抗体
CN101505787B (zh) 软骨障碍的治疗
TW202140523A (zh) 肢體痙攣之治療
US20250121028A1 (en) Use of link-tsg6 for the treatment of osteoarthritic pain
US9725484B2 (en) Methods and compositions for the treatment of bone remodeling disorders
Abou Zahr et al. Intra-cavernosal injection of botulinum toxin in the treatment of erectile dysfunction: a systematic review and meta-analysis
EP4401743B1 (en) Composition comprising sodium hyaluronate and amino acids for use in the orthopedic field
Marucha et al. Efficacy of enzyme replacement therapy on the range of motion of the upper and lower extremities in 16 Polish patients with mucopolysaccharidosis type II: A long-term follow-up study
Paul et al. Brunner & Suddarth's textbook of Canadian medical-surgical nursing
JP2022521237A (ja) 振戦治療のためのボツリヌス神経毒素の新規用途
KR20210054542A (ko) 신경 가소성을 유도하기 위한 방법 및 조성물
Nikolova et al. Degenerative joint diseases (osteoartrtrosis) and quality of life
KR20180035911A (ko) Fgf-18 화합물을 포함하는 조합 조성물
AU754982B2 (en) Compositions for promoting nerve regeneration
WO1994017818A1 (en) Methods for treating amyotrophic lateral sclerosis with cntf
Maddison Neuromyotonia
KR20210041580A (ko) 새로운 마이오카인 및 이의 용도
US20250288645A1 (en) USE OF GsMTx4 AND GsMTx4 CONJUGATES TO IMPROVE RECOVERY FROM JOINT INJURY
Shaher et al. Is platelet rich plasma a promising treatment for erectile dysfunction? the first 2-year follow up randomized controlled study
WO2019063581A1 (en) NEW THERAPY OF OSTEOARTHRITIC PAIN
Xiao et al. Effect Analysis of Botox Combined with Rehabilitation Training on Upper Limb Spasm after Hemiplegia.
Wang et al. Clinical effect of suspension training and Mulligan technique in combination with celecoxib in the treatment of chronic non-specific lower back pain.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination